Q2 FY2026 EarningsQ2 FY2026 results were mixed as revenue slightly beat consensus at $5.9M vs. $5.7M expected, driven by 19% sequential growth in YCANTH product sales. However, the company reported a significant earnings miss with a GAAP EPS of -$0.62 vs. the -$0.41 consensus, largely due to a $1.7M one-time legal settlement and elevated R&D spending for its Phase 3 common warts program. Management secured a new $27.5M credit facility, extending the cash runway into 2028, providing necessary liquidity for upcoming clinical milestones.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Verrica Pharmaceuticals(VRCA) the Revenue is 5.862 M (-53.85%), Beat estimate;the EBIT is -13.1 M (-967.4%), Miss estimate;the EPS is -0.62 (-3200%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B53.85%
0.01B54.83%
+0.00B0.98%
EBITMiss expectations
-0.01B967.35%
-0.01B702.61%
-0.00B264.74%
EPSMiss expectations
-0.623200.00%
-0.412150.00%
-0.21001,050.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf